Please login to the form below

European Society of Cardiology

This page shows the latest European Society of Cardiology news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s heart failure drug Farxiga scores FDA priority review

broad diabetes patient population, most of whom had no cardiovascular disease at enrolment, compared with placebo. ... AstraZeneca’s HFrEF trial of Farxiga – named DAPA-HF – was hailed as a ‘landmark trial’ when it was presented at last

Latest news

AZ’s Farxiga gets heart failure prevention okay from FDA

attack or stroke,” said Ruud Dobber, executive vice president of biopharmaceuticals at AZ. ... The HFrEF trial, called DAPA-HF, was presented at this year’s European Society of Cardiology (ESC) congress in Paris to some fanfare, showing that
TMC preps filings for inclisiran after final phase 3 trials hit the mark

burden. ORION-10 involved patients with atherosclerotic cardiovascular disease (ASCVD), and the results back up the earlier ORION-11 data in the same patient population which was presented at the European ... Society of Cardiology (ESC) congress
FDA fast-tracks AstraZeneca’s Farxiga in heart failure

Earlier this month, AZ revealed the results of the DAPA-HF trial of its diabetes therapy Farxiga, to an eager crowd at the European Society of Cardiology. ... This hard-to-treat form of the disease currently has no approved drug therapies.
AZ’s Farxiga heart failure results wow the ESC

Lead investigator John McMurray of the University of Glasgow presented the results at the European Society of Cardiology (ESC) congress in Paris over the weekend to an enthusiastic audience. ... non-diabetic population and make it an option for the
TMC rockets on data for twice-yearly cholesterol drug inclisiran

The results will be presented at the European Society of Cardiology meeting in Paris next week. ... control the LDL-cholesterol levels despite maximum doses of statin drugs, with or without Merck &Co’s add-on therapy Zetia (ezetimibe).

More from news
Approximately 2 fully matching, plus 44 partially matching documents found.

Latest Intelligence

Is it possible to change behaviour virtually?

One of my colleagues, Emma, has also incorporated virtual technology into a medical education programme. ... What value did the virtual mannequin add? . It was the first time ever a virtual mannequin had been used at the European Society of Cardiology
Helping European cardiologists keep up to date

But when asked about their propensity to take part in programmes in relation to: (1) the sponsoring organisation (independent bodies such as the European Society of Cardiology or an unrestricted grant ... Figure 4: EU5 average of preferences of online
Change drivers: multi-stakeholder education and collaboration

Professor John Camm, Chair of the European Society of Cardiology Committee for Guidelines on the Management of Atrial Fibrillation told me recently: “Well-meaning rewording of key messages to 'suit' different ... It resulted in improved cholesterol
Closing the treatment gap

Timescale:March 2009 to August 2009. The annual European Society of Cardiology Congress is the largest global cardiology meeting, attracting thousands of delegates and hundreds of journalists; the competition between pharmaceutical ... Merck, with a
A very favourable verdict

Timescale:July 2009 to December 2009. Guest delegates of DAIICHI SANKYO UK at the European Society of Cardiology Congress were subpoenaed to appear on a jury at The Formulary Court of ... meetings and will also roll out via a series of regional GP

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

Conference research case study

Communication strategies and marketing messages were to be crafted using the outcomes data which our client planned to launch at the European Society of Cardiology (ESC) annual congress. ... meant to our clients key customers and the overall impact of

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Account director: Competitive salary and bonus scheme

Account Manager (PR): Great Benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Publications director: Competitive salary and bonus scheme

Account Director: £Competitive Salary

Senior External Communications Lead: £Competitive Salary

Account Director, Medical Education: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Account Manager: £Competitive Salary

Experienced medical editor: Competitive salary and bonus scheme

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Account Director, Healthcare Communications: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Subscribe to our email news alerts

PMHub

Add my company

Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...